Butensky & Cohen Financial Security Inc. Has $4 Million Stake in Johnson & Johnson (NYSE:JNJ)

Butensky & Cohen Financial Security Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,632 shares of the company’s stock after buying an additional 1,947 shares during the quarter. Butensky & Cohen Financial Security Inc.’s holdings in Johnson & Johnson were worth $3,996,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Relyea Zuckerberg Hanson LLC grew its stake in Johnson & Johnson by 92.3% during the fourth quarter. Relyea Zuckerberg Hanson LLC now owns 34,076 shares of the company’s stock worth $4,928,000 after purchasing an additional 16,358 shares during the period. Saxon Interests Inc. boosted its holdings in shares of Johnson & Johnson by 13.3% during the 4th quarter. Saxon Interests Inc. now owns 7,730 shares of the company’s stock worth $1,118,000 after buying an additional 907 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $37,420,000. Tompkins Financial Corp lifted its position in shares of Johnson & Johnson by 16.1% during the 4th quarter. Tompkins Financial Corp now owns 37,374 shares of the company’s stock valued at $5,405,000 after acquiring an additional 5,177 shares during the period. Finally, Total Wealth Planning LLC boosted its stake in Johnson & Johnson by 4.6% during the fourth quarter. Total Wealth Planning LLC now owns 2,004 shares of the company’s stock worth $290,000 after acquiring an additional 89 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $147.03 on Friday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $353.99 billion, a PE ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. The stock’s 50 day moving average price is $148.51 and its 200-day moving average price is $155.96. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wells Fargo & Company lifted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup dropped their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.29.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.